Filing Flows › Comparisons › ALT vs JUNS
Altimmune vs Jupiter Neurosciences: ALT and JUNS compared
Altimmune is the larger company: $26K of revenue in its latest quarter (Q4 2025) against $24K for Jupiter Neurosciences (Q2 2026).
Where the money goes: ALT and JUNS
Altimmune (ALT) · Q4 2025
Altimmune, Q4 2025: revenue $26K (+420% year over year), net loss $27.4M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
Jupiter Neurosciences (JUNS) · Q2 2026
Jupiter Neurosciences, Q2 2026: revenue $24K, net loss $2.3M, operating cash flow −$2.3M. The chart follows the revenue to costs, profit and cash.
| Altimmune (ALT) | Jupiter Neurosciences (JUNS) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q2 2026 |
| Revenue | $26K | $24K |
| Revenue growth, Y/Y | +420% | — |
| Operating margin | n/m | n/m |
| Net earnings | −$27.4M | −$2.3M |
| Operating cash flow | −$19.4M | −$2.3M |
Questions
Which is bigger, Altimmune or Jupiter Neurosciences?
Altimmune is the larger company: $26K of revenue in its latest quarter (Q4 2025) against $24K for Jupiter Neurosciences (Q2 2026).
More: Altimmune earnings · how Altimmune makes money · Jupiter Neurosciences earnings · how Jupiter Neurosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 6, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.